Latest News and Press Releases

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Diabetic Macular Edema - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial...

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Retinal Vein Occlusion Treatment Market by Treatment Type (Anti-VEGF Injection, Corticosteroid Treatment, Laser Therapy), Age Group (40-60, Above 60,...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Global Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other...

Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Macular Edema Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...

RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...

Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...

EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...

THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration

Richmond, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to a research report "Diabetic Retinopathy Market”, By Type (Proliferative Diabetic Retinopathy, Diabetic Macular Edema (DME)), Treatment Type...